Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cleave names new VP, clinical development

This article was originally published in Scrip

Executive Summary

Cleave Biosciences has named Dr Kanya Rajangam vice-president of clinical development. Dr Rajangam will lead Cleave's ongoing clinical trials and design future studies to evaluate drug candidate CB-5083 in hematological and solid tumor malignancies, as well as advance other internally discovered compounds into development. Most recently she was executive director of the oncology and immuno-oncology program at Nektar Therapeutics. Cleave also announced that chief medical officer Dr Alessandra Cesano is leaving the company to pursue other opportunities.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts